Here are the 3 big things we're watching in the stock market this week

Earnings season kicks off Tuesday with JPMorgan, Citi, Bank of America and (before the bell) Wells Fargo and Goldman Sachs, with investors focused on whether AI spending is improving results and on key profitability metrics like ROTCE (Wells needs ROTCE to stay on a path to ~17%-18%) and efficiency ratios. At the same time, CPI (June) is due Tuesday (FactSet: 3.8% YoY, -0.2% MoM) and PPI (June) Wednesday (FactSet: +6.2% YoY, -0.2% MoM), both shaping Fed expectations for coming rate decisions. The article flags easing oil-led inflation pressures from WTI falling from the low $90s to just below $70 by month-end, but notes renewed Hormuz tensions could offset that. J&J also reports Wednesday with Street expectations of $25.05B revenue and $2.85 EPS, while investors watch growth drivers including Darzalex, Tremfya and the Icotyde launch trajectory.

Analysis

The real signal this week is not CPI itself; it is whether bank commentary confirms that growth is still intact while credit remains orderly. That matters most for GS versus WFC: GS has more upside leverage to a normalized capital-markets cycle and can defend a premium multiple if ROTCE stays durable, while WFC still needs proof that expense control and consumer health are not deteriorating. A soft inflation print may lower rates, but that is not uniformly good for banks—short-end relief helps funding costs, yet a flatter NII trajectory can offset it.

JNJ looks more like a “good company, high bar” setup than a true re-rating candidate. After the healthcare rotation, the stock can underperform on merely conservative guidance even if core execution is fine; the market is paying for pipeline conversion, not just defensiveness. If management fails to show monetization visibility on newer launches, capital should rotate toward higher-growth healthcare names with clearer self-help, and any JNJ pullback is likely to be bought only if pharma growth remains above mid-single digits.

The bigger second-order macro risk is energy: if oil reverses higher, the benign inflation narrative can unwind faster than the Fed can react, pressuring transports, airlines, and other fuel-sensitive cash generators like UAL and JBHT. The contrarian view is that consensus is over-anchored to backward-looking CPI/PPI and underweight the supply shock path; a Hormuz-related spike would hit equities through margins first, then through rates. That makes this a months-long inflation/trade-risk story, not a one-day data print story.

Key Decisions for Investors

• Long GS / short WFC into Tuesday’s earnings prints, 1-3 week horizon. Favor GS if investment-banking and markets revenue show durability; WFC is the cleaner short if expense discipline or consumer commentary disappoints. Falsifier: WFC delivers a clean beat and raises ROTCE/efficiency guidance.
• Reduce or hedge JNJ ahead of Wednesday if already overweight healthcare defensives. Best expression is a 2-6 week call-spread sale or outright trim on strength, because the setup is more about valuation compression than fundamental breakdown. Falsifier: clear evidence of accelerating prescription growth and raised FY guidance.
• Tactically add UAL and JBHT only on confirmation that inflation/oil remain contained after CPI/PPI. These are 1-3 month beneficiaries of lower fuel and easier pricing pressure, but the position should be small until oil stability is confirmed. Falsifier: WTI back above the mid-$70s.
• No broad market long based solely on CPI. If the print is soft, fade the initial rate-cut rally in rate-sensitive cyclicals unless banks and consumer-exposed names confirm better demand in earnings calls.